PureTech Health (LSE:PRTC) has reported further progress from its Founded Entity, Seaport Therapeutics, which announced positive multiple-ascending dose results from a Phase 1 proof-of-concept study evaluating GlyphAgo. The oral prodrug of agomelatine has been engineered to improve lymphatic absorption while limiting liver exposure. Data from the trial showed that repeated dosing over seven days produced therapeutic agomelatine concentrations alongside favourable safety, tolerability and pharmacokinetic profiles, with no liver-related adverse events reported. The findings support dose selection for future studies and reinforce GlyphAgo’s potential as a differentiated treatment option for generalized anxiety disorder.
The latest results build on earlier single-ascending dose and crossover studies that demonstrated substantially higher bioavailability and reduced pharmacokinetic variability compared with standard agomelatine. Together, the findings strengthen confidence in Seaport’s development strategy and provide further validation of its proprietary Glyph platform. The company intends to move GlyphAgo into two parallel Phase 2 studies in generalized anxiety disorder beginning in 2026 and 2027, with one trial focused on sleep-related pharmacology and the other potentially serving as a registration-enabling efficacy study. The programme reflects PureTech’s strategy of creating, developing and scaling platform-based neuropsychiatric therapies through its Founded Entities.
While the clinical and portfolio developments are encouraging, PureTech’s overall outlook remains tempered by continued operating losses, negative free cash flow and a relatively modest revenue base. These challenges are partly balanced by a solid balance sheet and recent improvements in operating performance. Updates from management regarding clinical progress, portfolio advancement and funding runway have strengthened the investment case, although execution and financing risks remain significant. Technical indicators remain broadly neutral, while valuation metrics continue to be constrained by negative earnings and the absence of dividend payments.
More about PureTech Health
PureTech Health is a UK-listed biotherapeutics company that operates a hub-and-spoke model, creating and developing Founded Entities that combine clinically validated pharmacology with targeted innovation to address significant unmet medical needs. Through this approach, the company seeks to generate and advance new therapeutic platforms across a range of disease areas.
One of its Founded Entities, Seaport Therapeutics, is a Nasdaq-listed clinical-stage biotechnology company focused on developing next-generation neuropsychiatric medicines. Using its proprietary Glyph platform, Seaport aims to improve the bioavailability, consistency and safety profile of established therapeutic mechanisms for conditions including anxiety, depression and related neurological disorders.
Leave a Reply